Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$9.20
+1.3%
$7.50
$4.62
$13.47
$575.79M0.291.30 million shs3.01 million shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$32.00
-0.2%
$32.26
$25.66
$40.28
$1.79B0.7477,192 shs212,566 shs
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$3.28
+2.5%
$3.22
$2.65
$9.55
$181.52M0.85481,437 shs303,242 shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$34.70
+4.0%
$32.54
$26.74
$46.00
$2.66B1.1630,958 shs492,450 shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
+1.27%-0.92%+40.81%+34.04%-13.42%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-0.23%+2.55%-0.73%-2.28%+23.01%
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
+2.50%+10.44%0.00%+6.15%-57.57%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+4.00%+7.78%+12.97%+18.04%-3.92%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.2244 of 5 stars
2.02.00.04.02.31.70.6
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.5737 of 5 stars
2.22.00.04.12.10.00.0
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.6874 of 5 stars
3.61.00.04.61.10.80.6
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.3237 of 5 stars
4.52.00.00.02.62.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
2.00
Hold$8.93-2.85% Downside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.33
Hold$36.0012.52% Upside
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
3.13
Buy$13.39308.23% Upside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$54.8257.96% Upside

Current Analyst Ratings Breakdown

Latest XENE, SUPN, SAGE, and VYGR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$8.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$12.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$8.00 ➝ $8.50
6/16/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/14/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $47.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$58.00 ➝ $55.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$53.00 ➝ $53.00
5/13/2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$41.24M13.96N/AN/A$7.60 per share1.21
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$661.82M2.71$4.16 per share7.69$18.76 per share1.71
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
$80M2.27N/AN/A$5.49 per share0.60
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$9.43M282.38N/AN/A$9.90 per share3.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$73.86M$1.1128.8222.22N/A9.27%12.23%9.17%8/5/2025 (Estimated)
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$65M-$1.46N/AN/AN/A-126.49%-27.36%-21.06%8/5/2025 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$234.33M-$3.23N/AN/AN/AN/A-32.44%-30.84%8/14/2025 (Estimated)

Latest XENE, SUPN, SAGE, and VYGR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.96N/AN/AN/A$16.69 millionN/A
5/12/2025Q1 2025
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$0.90-$0.83+$0.07-$0.83$1.64 million$7.50 million
5/6/2025Q1 2025
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
-$0.35-$0.53-$0.18-$0.53$13.55 million$6.47 million
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
9.13
9.13
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
2.44
2.26
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
N/A
6.10
6.10
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
17.66
17.66

Institutional Ownership

CompanyInstitutional Ownership
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
48.03%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%
CompanyEmployeesShares OutstandingFree FloatOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million59.18 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
58055.99 million51.06 millionOptionable
Voyager Therapeutics, Inc. stock logo
VYGR
Voyager Therapeutics
10055.34 million51.80 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21076.73 million72.50 millionOptionable

Recent News About These Companies

Xenon Appoints CEO Ian Mortimer as Interim CFO
Xenon Joins the Russell 3000® and Russell 2000® Indexes
Cantor Fitzgerald Estimates XENE FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$9.20 +0.12 (+1.27%)
Closing price 07/3/2025 02:52 PM Eastern
Extended Trading
$9.20 0.00 (0.00%)
As of 07/3/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$32.00 -0.08 (-0.23%)
Closing price 07/3/2025 01:31 PM Eastern
Extended Trading
$32.00 0.00 (0.00%)
As of 07/3/2025 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.

Voyager Therapeutics stock logo

Voyager Therapeutics NASDAQ:VYGR

$3.28 +0.08 (+2.50%)
Closing price 07/3/2025 03:33 PM Eastern
Extended Trading
$3.20 -0.07 (-2.29%)
As of 07/3/2025 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$34.70 +1.33 (+4.00%)
As of 07/3/2025 02:52 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.